Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer
Molecular Oncology · 2025
DOI: 10.1002/1878-0261.13791 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2025. Verfasst von Zuojian Hu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Stomatological Hospital & School of Stomatology & Institutes of Biomedical Sciences, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Metabolomics, Biomarkers, Tumor. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Guangxi Natural Science Foundation Project.
Abstract (Originalsprache)
Colorectal cancer (CRC) is a prevalent malignant tumor worldwide, with a high mortality rate due to its complex etiology and limited early screening techniques. This study aimed to identify potential biomarkers for early detection of CRC utilizing targeted metabolite profiling of platelet‐rich plasma (PRP). Based on multiple reaction monitoring (MRM) mode, liquid chromatography tandem mass spectrometry (LC–MS/MS) analysis identified metabolites in PRP collected from patients with CRC ( n = 70) and healthy controls ( n = 30). A total of 302 metabolites were identified and quantified in this study, including various categories such as lipids, lipid mediators, amino acids, and derivatives, organic acids and derivatives, nucleotides and derivatives, alkaloids, carbohydrates, vitamins and derivatives, and others. The differential analysis revealed that five carbohydrates and organic acids (lactose, glycerol‐3‐phosphate, 2−hydroxyglutaric acid, isocitric acid, and citric acid) involved in the carbohydrate metabolism pathway displayed consistent upregulation within PRP derived from patients with CRC. To further validate the abundance of differential metabolites, 10 pairs of CRC tissues, adjacent tissues, and matched PRP were collected. Ultimately, five carbohydrate metabolites were validated in PRP, and compared with carcinoembryonic antigen (CEA) and cancer antigen 19‐9 (CA199), the five carbohydrate metabolites significantly improved the specificity of differentiating patients with CRC from healthy controls. Furthermore, the diagnostic efficacy of the combined five‐carbohydrate metabolite panel was superior to that of individual metabolites, CEA and CA199. The sensitivity, specificity, and AUC of the metabolite panel in distinguishing patients with CRC from healthy controls were 90.00%, 96.67%, and 0.961 (95% CI 0.922–0.998), respectively. Collectively, metabolomics was used to identify and validate differential metabolites in the PRP of CRC, which may serve as potential early screening markers for patients with CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Stomatological Hospital & School of Stomatology & Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
- Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University, Nanning, China.
- Department of Colorectal & Anal Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, China.
ORCID-Profile: Hongxiu Yu
Förderung
- Guangxi Natural Science Foundation Project
Zitieren
APA
Hu, Z., Shen, F., Liu, Y., Zhong, Z., Chen, Y., Xia, Z., Mo, C., & Yu, H. (2025). Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer. Molecular Oncology. https://doi.org/10.1002/1878-0261.13791
Vancouver
Hu Z, Shen F, Liu Y, Zhong Z, Chen Y, Xia Z, et al. Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer. Molecular Oncology. 2025. doi:10.1002/1878-0261.13791
BibTeX
@article{Hu2025,
author = {Hu, Zuojian and Shen, Fenglin and Liu, Yang and Zhong, Ziqing and Chen, Yongling and Xia, Zhiyuan and Mo, Cuiju and Yu, Hongxiu},
title = {Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer},
journal = {Molecular Oncology},
year = {2025},
doi = {10.1002/1878-0261.13791}
}
EUVIMED